As per a recent randomized, double-blinded, placebo-controlled parallel analysis led by P. Gazerani and colleagues, the Vitamin-D3 supplementation found to reduce migraine attacks in the migraine patients. Vitamin D shows a substantial role in managing various kinds of pain conditions. It is evident from previous studies that the migraineurs exhibit low levels of vitamin D, and this study examined whether vitamin D supplementation would be advantageous in migraine management or not.

The treatment group showed a more significant reduction in migraine days from  6.14 ± 3.60 to 3.28 ± 3.24 than placebo (5.72 ± 4.52 to 4.93 ± 3.24). The treatment group also exhibited a low frequency of migraine than the placebo group at 24th week. No significant difference was noticed in pressure pain thresholds, temporal summation, migraine severity and 1,25(OH)2D levels. The D3-Vitamin group exhibited considerably higher levels of 25(OH)D as compared to the placebo group. No side-effects were recorded during the whole investigation.

These findings explain the remarkable role of vitamin D in migraine management, but more extensive studies are needed to validate vitamin D3 as a prophylactic alternative for migraine.